Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Expects to Resolve Eco PCR System Backlog by End of June

Premium

Illumina CEO Jay Flatley said this week that the company has addressed previously reported backlog issues related to the company's Eco real-time PCR instrument.

"Demand for our Eco real-time PCR instrument is continuing to build nicely," Flatley said during a conference call discussing the company's Q1 earnings, released earlier this week. "We experienced some initial challenges in ramping manufacturing that we believe are now behind us. We're significantly scaling Eco production and expect to deliver the product with standard lead times by the end of this quarter."

Illumina launched the Eco last July following the acquisition of Helixis, which developed the platform's underlying technology. The sub-$15,000 system is aimed at researchers desiring a personal benchtop PCR instrument with performance comparable to more expensive systems often found in core labs (PCR Insider, 7/29/10).

In January, discussing Illumina's Q4 and full-year 2010 financial results, Flatley told investors that Q4 2010 orders for the Eco tripled from Q3, but that the company was experiencing "constraints" in its supply chain, and planned to move manufacturing of the product to its Singapore facility this year.

lllumina this week reported a 47 percent increase in Q1 2011 revenues, fueled by growth in its sequencing business and demand for its HiSeq 2000 systems.

Filed under

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.